ANGPT2 (Angiopoietin 2)

The complete response (CR) rate was 33.3% in the high-level group versus 66.7% in the low-level group (p = 0.003), and the overall response (OR) rate was 35.9% versus 74.4% (p = 0.001). CSF exosomal ANGPTL2 is a novel, independent prognostic marker in PCNSL.

ANGPT2 rs2959822 influences the survival outcomes of patients with prostate cancer undergoing ADT. In addition to angiogenesis, ANGPT2 plays a critical role in prostate cancer progression by promoting EMT and modulating the tumor immune microenvironment.

JDF exhibits efficacy in reducing hypoxia-induced angiogenesis in HCC through a mechanism involving the Aurora A/STAT3/IL-8 signaling pathway. Therefore, JDF holds promise as a potential therapeutic approach for targeting HCC angiogenesis. Please cite this article as: Zhong MF, Luo YJ, Guo YY, Xiang S, Lin WF. Jiedu Fang inhibits hypoxia-induced angiogenesis in hepatocellular carcinoma by targeting Aurora A/STAT3/IL-8 signaling pathway. J Integr Med. 2025; Epub ahead of print.

ANGPT2 demonstrates potential as a biomarker for cancer diagnosis and prognosis, with evidence suggesting its involvement in immune microenvironment regulation and associated gene networks. Therapeutic approaches targeting ANGPT2, either as a stand-alone treatment or in combination with immunotherapies, could offer new and effective strategies for future cancer treatments.

Multimodal MC was administered continuously, combining low doses of capecitabine, cyclophosphamide, and aspirin. The presence of liver metastases, baseline plasmatic levels of Ang2 and CXCL14, as well as the induction of PD1 on T-cells are potential biomarkers for efficacy. These results feature a potential subset of diseases where MC might be a promising cost-effective and well-tolerated therapeutic option.

Finally, through the investigation of the ubiquitin-mediated degradation pathway of OGDH, it was demonstrated that ANGPT2 inhibited the protein degradation of OGDH via deubiquitination, thereby maintaining its stability. In summary, UL82 promotes CRC cell proliferation by upregulating ANGPT2, which inhibits the ubiquitin-mediated degradation of OGDH, suggesting that targeting the UL82/ANGPT2/OGDH axis may offer a potential clinical strategy for the diagnosis of CRC.

BMI1 promotes angiogenesis in CRC by upregulating ANGPT2 expression. High BMI1 and ANGPT2 levels served as independent prognostic factors for tumor progression, highlighting their potential as therapeutic targets for CRC management.

TEMs promote angiogenesis in CIBT through a paracrine mechanism, and the recruitment of TEMs to CIBT is regulated by the miR-126-5p/TRPS1/ANGPT2 pathway.

Currently, monotherapy with PD-1/PD-L1 inhibitors, or their combination with bevacizumab, is considered the standard therapeutic approach for LUAD...Functionally, IFN-γ limits the migration, proliferation, and tube formation of ECs. In conclusion, our results revealed a novel mechanism wherein IFN-γ-mediated inhibition of ANGPT2-Tie2 facilitates vascular normalization during immunotherapy in LUAD, which performs an essential function in the antitumor efficacy of immunotherapy.

ANGPTL2 is associated with host wasting-related poor prognosis through its association with systemic inflammation in patients with colorectal cancer. These findings overall provide novel insight into ANGPTL2 function and illustrate the essential role of tumor-host interactions in the prognosis of cancer survivors.

These findings emphasize the potential of ANGPT2 and CEMIP as biomarkers for LC progression and prognosis. To our knowledge, no previous study has evaluated the presence and quantification of ANGPT2 and CEMIP in EV cargo from lung cancer patients. To further validate their role in cancer progression, functional studies should explore the mechanistic effects of EV-associated ANGPT2 and CEMIP on angiogenesis, immune modulation, cell migration, extracellular matrix remodeling, and tumor progression in lung cancer models.

Additionally, we evaluated the associations of the analyzed genetic changes with the clinical and laboratory parameters of the disease and the response to bortezomib/thalidomide-based therapies. The ANGPT2 protein is a proangiogenic factor, and its concentration is significantly greater in MM patients than in healthy individuals, which was also confirmed in our research. Therefore, this protein with VEGF and HB-EGF, should be considered in the future as a markers of angiogenesis in MM.